USPTO Examiner SHIAO REI TSANG - Art Unit 1691

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19261853COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDSJuly 2025December 2025Allow610NoNo
19258578PHARMACEUTICAL COMPOSITIONS OF NILOTINIBJuly 2025January 2026Allow610NoNo
19227609METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINEJune 2025January 2026Allow810NoNo
19227593METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINEJune 2025January 2026Allow810NoNo
19206909PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEMay 2025October 2025Allow510NoNo
19205979APPLICATION OF GLYCEROL MONODECANOATE IN PREPARATION OF HYPOGLYCEMIC DRUG OR FUNCTIONAL FOODMay 2025October 2025Allow510NoNo
19059754Testosterone Dodecanoate Compositions and MethodsFebruary 2025November 2025Allow920NoNo
19030399AMINO ACID COMPOSITIONSJanuary 2025September 2025Allow810YesNo
19030439AMINO ACID COMPOSITIONSJanuary 2025September 2025Allow810NoNo
19021386METHOD FOR TREATING A DISORDERJanuary 2025August 2025Allow710NoNo
19008588DIETARY GLYCINE AND SERINE RESTRICTION FOR CANCER TREATMENTJanuary 2025June 2025Allow510YesNo
19005921USE OF TYROSOL AS A PHYSIOLOGICAL ENHANCER OF CREATINE AND ITS APPLICATION IN CONTINUOUS HIGH INTENSITY EXERCISEDecember 2024July 2025Allow620NoNo
18932667PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEOctober 2024April 2025Allow510NoNo
18924252Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyOctober 2024January 2025Allow310NoNo
18855563INTRANASAL ADMINISTRATION OF N-ACETYLCYSTEINE AND USES THEREOFOctober 2024December 2025Allow1410NoNo
18853657ACETYL SALICYLIC ACID COMPOSITION FOR INTRAVENOUS ADMINISTRATION, ITS STORAGE, PRODUCTION AND USEOctober 2024June 2025Allow810NoNo
18898132GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATESeptember 2024March 2025Allow510NoNo
18790828Dosage RegimenJuly 2024April 2025Allow910NoNo
18751014PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024February 2025Allow810NoNo
18680287ESKETAMINE FOR THE TREATMENT OF DEPRESSIONMay 2024March 2025Abandon910NoNo
18670619EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024April 2025Abandon1120NoNo
18595759METHODS OF USING FACTOR B INHIBITORSMarch 2024August 2025Allow1810NoNo
18435109PRODRUGS OF L-BHDU AND METHODS OF TREATING VIRAL INFECTIONSFebruary 2024June 2025Allow1710NoNo
18426914SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTIONJanuary 2024August 2025Allow1910NoNo
18419354NOVEL EBSELEN ANALOGUES LOADED NANOEMULSIONJanuary 2024August 2024Allow710NoNo
18416811COMPOSITION COMPRISING A DIINDOLYLMETHANE AND A RETINOID TO TREAT A SKIN CONDITIONJanuary 2024September 2025Allow2020NoNo
18409208REDUCED DOSE METAXALONE FORMULATIONSJanuary 2024July 2025Allow1810NoNo
18405593COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTSJanuary 2024June 2025Allow1810NoNo
18403027TREATMENT AND DIAGNOSIS OF MELANOMAJanuary 2024August 2025Allow2010NoNo
18394155COMPOSITION COMPRISING COMBINATION OF RAPAMYCIN AND METFORMIN AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASESDecember 2023May 2025Allow1710NoNo
18390000METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTSDecember 2023October 2025Allow2210NoNo
18545858Lipid Formulations for Delivery of Messenger RNADecember 2023December 2025Abandon2410NoNo
18534800COT MODULATORS AND METHODS OF USE THEREOFDecember 2023July 2025Abandon2010NoNo
18528397COMPOSITIONS AND METHODS FOR MODULATING HEXIM1 EXPRESSIONDecember 2023July 2025Abandon2010NoNo
18524947SOLID FORMS OF A DUAL RAF/MEK INHIBITORNovember 2023September 2025Allow2110NoNo
18523772METHOD TO ALLEVIATE THE SYMPTOMS OF PMSNovember 2023February 2025Allow1400NoNo
18519801STABLE TREPROSTINIL PRODRUGSNovember 2023August 2025Allow2020NoNo
18511262ATHLETIC PERFORMANCE ENHANCEMENT COMPOSITION USING MENTHOLNovember 2023July 2025Allow2010NoNo
18502543TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONSNovember 2023July 2025Allow2110NoNo
18500175TOPICAL FERTILITY PROMOTING PRODUCT AND MANUFACTURING METHODNovember 2023May 2025Allow1810NoNo
18484823SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATIONOctober 2023July 2025Allow2110NoNo
18478483COMBINATION THERAPY FOR TREATING CANCERSeptember 2023July 2025Abandon2110NoNo
18370116INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONESeptember 2023July 2025Allow2210NoNo
18468266PHARMACEUTICAL COMPOSITIONS OF NILOTINIBSeptember 2023May 2025Allow2010NoNo
18242276COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDERSeptember 2023February 2026Abandon2920NoNo
18240049Regimens of Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsAugust 2023December 2025Allow2720NoNo
18451520METHODS OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASEAugust 2023June 2025Abandon2210NoNo
18365549TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIBAugust 2023June 2025Abandon2210NoNo
18364058NON-LINEAR DOSING OF MIRDAMETINIBAugust 2023February 2025Allow1810NoNo
18227210ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS FOR THE TREATMENT AND/OR PREVENTION OF RESPIRATORY ILLNESSESJuly 2023April 2025Allow2110NoNo
18345292USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTIONJune 2023April 2025Allow2210NoNo
18216307METHODS OF TREATMENT USING AN MTORC1 MODULATORJune 2023April 2025Allow2210NoNo
18343267ALK2 INHIBITORS FOR THE TREATMENT OF ANEMIAJune 2023April 2025Allow2210NoNo
18341023FGFR2 INHIBITORS FOR THE TREATMENT OF CHOLANGIOCARCINOMAJune 2023March 2025Allow2110NoNo
18336440Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesJune 2023April 2025Abandon2201NoNo
18202790COMPOSITION, USES, AND METHODS OF TREATING SPINAL DISC DEGENERATION THROUGH SONIC HEDGEHOG SIGNALING PATHWAYMay 2023February 2026Allow3221NoNo
18202704TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90May 2023July 2025Allow2620NoNo
18201106PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANIC SALT, PRODUCTION PROCESS AND USEMay 2023January 2025Allow1910NoNo
18317881METHODS FOR THE ADMINISTRATION OF ILOPERIDONEMay 2023June 2025Abandon2510NoNo
18252553NEUTROPHIL-TO-LYMPHOCYTE RATIO DECREASING AGENTMay 2023February 2026Allow3310NoNo
18311715N1-Pyrazolospiroketone Acetyl-CoA Carboxylase InhibitorsMay 2023March 2025Allow2210NoNo
18310041TRIPTAN MICROPORATION DELIVERY SYSTEMMay 2023February 2025Allow2210NoNo
18033993ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOFApril 2023March 2026Allow3510NoNo
18305826Compositions And Methods For Treating AutismApril 2023June 2025Allow2610NoNo
18136210GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT CERVICAL CANCERApril 2023February 2025Allow2210NoNo
18130749Therapeutic Uses of Compounds Having Combined Sert, 5-HT3 and 5-HT1a ActivityApril 2023May 2025Abandon2510NoNo
18247113COMPLEX CONTAINING WATER-SOLUBLE BETA-BLOCKER AND LECITHINMarch 2023February 2026Allow3510NoNo
18028202Extended Release Pharmaceutical FormulationMarch 2023December 2025Allow3310NoNo
18246442COMPOSITIONS AND METHODS USING XANTHAN GUM TO STABILIZE AT LEAST ONE UROLITHIN IN AN AQUEOUS MATRIXMarch 2023December 2025Allow3310NoNo
18027608METHODS AND COMPOSITIONS TO TREAT AND PREVENT VIRAL INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROMEMarch 2023February 2026Allow3410NoNo
18123080MACROCYCLES FOR USE IN TREATING DISEASEMarch 2023February 2026Abandon3510NoNo
18119679METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONEMarch 2023May 2025Abandon2610NoNo
18178941PREVENTION OR TREATMENT OF DISEASE STATES DUE TO METAL DIS-HOMEOSTASIS VIA ADMINISTRATION OF POSIPHEN TO HEALTHY OR SICK HUMANSMarch 2023April 2025Allow2610NoNo
18024572PYRROLIDINE COMPOUNDS TO TREAT XERODERMA PIGMENTOSUMMarch 2023March 2026Abandon3610NoNo
18116506MOLYBDENUM IMIDO ALKYL/ALLYL COMPLEXES FOR DEPOSITION OF MOLYBDENUM-CONTAINING FILMSMarch 2023November 2025Allow3310NoNo
18115593METHODS OF TREATING FIBROSISFebruary 2023January 2025Allow2310NoNo
18115598METHODS OF TREATING FIBROSISFebruary 2023December 2025Allow3410NoNo
18041911TOPICAL COMPOSITIONFebruary 2023November 2025Allow3310NoNo
17996867COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASESFebruary 2023October 2025Allow3601NoNo
18169296FOSPROPOFOL METHODS AND COMPOSITIONSFebruary 2023March 2025Allow2510NoNo
18020774COMPOSITION FOR PREVENTION AND TREATMENT OF MYOPATHYFebruary 2023September 2025Allow3100NoNo
18106616Food Safety MethodFebruary 2023December 2024Allow2210NoNo
18019527SALT INDUCIBLE KINASE INHIBITORSFebruary 2023November 2025Allow3410NoNo
18155694METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORSJanuary 2023May 2025Abandon2810NoNo
18155483METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORSJanuary 2023January 2025Allow2410NoNo
18013355PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASEDecember 2022November 2025Allow3510NoNo
18012908METHOD AND COMPOUND FOR THE TREATMENT AND ELIMINATION OF AN IMMUNODEFICIENCY CONDITIONDecember 2022February 2026Abandon3810NoNo
18012411WATER SOLUBLE 3-O-ACETYL-11-KETO-B-BOSWELLIC ACID AND METAL ION COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND USES THEREOFDecember 2022January 2026Allow3710NoNo
18069555USE OF FERRIC CITRATE IN THE TREATMENT OF IRON-DEFICIENCY ANEMIADecember 2022February 2026Allow3810NoNo
18002494METHOD OF ACHIEVING HIV VIRAL REMISSION USING LONG-ACTING ANTIRETROVIRAL AGENTSDecember 2022January 2026Allow3710NoNo
18083922COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONEDecember 2022March 2025Allow2710NoNo
180093062-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORSDecember 2022September 2025Allow3410NoNo
18000880COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA (OSA)December 2022November 2025Allow3610NoNo
18061985NEW TREATMENT OF SMADecember 2022March 2025Allow2710NoNo
18008425COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERSDecember 2022February 2026Allow3811NoNo
18008005GLUCOKINASE ACTIVATOR FOR TREATING DIABETES WITH HEPATIC IMPAIRMENTDecember 2022March 2026Abandon3910NoNo
18073419STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USESDecember 2022February 2025Allow2610NoNo
17986488SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPYNovember 2022December 2024Allow2510YesNo
17921803COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANDROGRAPHOLIDE AND MELATONIN COMBINATION THERAPYOctober 2022December 2025Allow3810NoNo
17996812METHODS OF USING RHO KINASE INHIBITORS TO TREAT ALZHEIMER'S DISEASEOctober 2022February 2025Allow2820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIAO, REI TSANG.

Strategic Value of Filing an Appeal

Total Appeal Filings
7
Allowed After Appeal Filing
3
(42.9%)
Not Allowed After Appeal Filing
4
(57.1%)
Filing Benefit Percentile
70.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SHIAO, REI TSANG - Prosecution Strategy Guide

Executive Summary

Examiner SHIAO, REI TSANG works in Art Unit 1691 and has examined 192 patent applications in our dataset. With an allowance rate of 97.4%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner SHIAO, REI TSANG's allowance rate of 97.4% places them in the 89% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SHIAO, REI TSANG receive 1.19 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SHIAO, REI TSANG is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -32.2% benefit to allowance rate for applications examined by SHIAO, REI TSANG. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 44.4% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 90% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 96.3% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 21.9% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.